FDA Approval: Siltuximab for the Treatment of Patients With Multicentric Castleman Disease

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-1678
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Siltuximab: A Targeted Therapy for Idiopathic Multicentric Castleman Disease

Immunotherapy
OncologyAllergyImmunology
2016English

Biologic Agents in the Treatment of Multicentric Castleman Disease

Turkish Thoracic Journal
PulmonaryRespiratory Medicine
2018English

Long-Term Safety of Siltuximab in Patients With Idiopathic Multicentric Castleman Disease: A Prespecified, Open-Label, Extension Analysis of Two Trials

The Lancet Haematology
Hematology
2020English

Clinicopathologic Characteristics of 342 Patients With Multicentric Castleman Disease in Japan

Modern Rheumatology
MedicineRheumatology
2020English

Multicentric Castleman Disease: An Unusual Breast Lump

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Predictors of Response to Anti-Il6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial Data

British Journal of Haematology
Hematology
2018English

FDA Approval: Blinatumomab for Patients With B-Cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission With Minimal Residual Disease

Clinical Cancer Research
Cancer ResearchOncology
2019English

Multicentric Castleman' S Disease Manifesting in the Lung: Clinical, Radiographic, and Pathologic Findings and Successful Treatment With Corticosteroid and Cyclophosphamide.

Internal Medicine
Internal MedicineMedicine
2003English

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy